8-K: Callan JMB Q3 2025: Strategic Growth Amidst Rising Losses

Callan JMB reports increased losses in Q3 2025 despite strategic expansions into food sampling and international markets, alongside key contract extensions.

Summary

• Callan JMB Inc. announced its financial results for the third quarter ended September 30, 2025, reporting a net loss of $2.73 million for the quarter and $5.37 million for the nine months.
• Revenue for Q3 2025 was $1.4 million, a slight decrease from $1.435 million in Q3 2024, and $4.6 million for the nine months, down from $5.211 million in the prior year.
• Gross profit for Q3 2025 was $0.5 million, with a nine-month gross profit of $1.8 million.
• Selling, General, and Administrative (SG&A) expenses significantly increased to $2.4 million for Q3 2025 and $6.3 million for the nine months, primarily due to costs associated with being a public entity.
• The company expanded its compliance-driven logistics platform into the food sampling industry and entered a preliminary agreement to install oral drug delivery equipment at its Texas cGMP facility.
• Callan JMB established a subsidiary in India, Callan JMB Services (India) Private Limited, with plans for a temperature-controlled pharmaceutical storage and distribution warehouse, securing an agreement with Walkers Pharmaceuticals Ltd.
• The long-term contract with the City of Chicago was extended through June 2026, with an additional $1.5 million in funding, bringing the total contract value to $9.1 million.
• The proprietary Sentry Monitoring System was upgraded to version 4.0, transitioning from Java to HTML5 for enhanced mobile temperature monitoring capabilities.

Sentiment

Score: 4

Explanation: The sentiment is moderately negative due to significant increases in operating and net losses, coupled with a decline in revenue. While strategic initiatives and contract extensions are positive, the financial performance indicates substantial challenges in achieving profitability, especially with rising SG&A costs.

Positives

• Expanded reclamation operations into the food sampling sector, leveraging existing compliance-driven logistics capabilities.
• Entered a preliminary agreement to install innovative oral drug delivery manufacturing equipment at the Texas cGMP facility, supporting onshoring initiatives.
• Established Callan JMB Services (India) Private Limited, with plans for a temperature-controlled pharmaceutical warehouse and an agreement with Walkers Pharmaceuticals Ltd.
• Extended the emergency preparedness contract with the City of Chicago through June 2026, adding $1.5 million in funding for a total contract value of $9.1 million.
• Upgraded the Sentry Monitoring System to version 4.0 (HTML5), enhancing device-agnostic access to critical temperature monitoring.
• Cash and cash equivalents increased to $2.8 million as of September 30, 2025, from $2.1 million at December 31, 2024.

Negatives

• Revenue for the three months ended September 30, 2025, decreased slightly to $1.4 million from $1.435 million in the prior year, attributed to a seasonal decline in emergency preparedness services.
• Revenue for the nine months ended September 30, 2025, decreased to $4.6 million from $5.211 million in the prior year.
• Selling, General, and Administrative (SG&A) expenses significantly increased to $2.4 million for Q3 2025 (from $1.245 million in Q3 2024) and $6.3 million for the nine months (from $3.146 million in 9M 2024), primarily due to public entity-related consulting, professional fees, and marketing expenses.
• Loss from operations widened significantly to $1.9 million for Q3 2025 (from $0.78 million in Q3 2024) and $4.5 million for the nine months (from $1.0 million in 9M 2024).
• Net loss increased substantially to $2.73 million for Q3 2025 (from $0.805 million in Q3 2024) and $5.37 million for the nine months (from $0.998 million in 9M 2024).
• Net loss per common share worsened to $(0.61) for Q3 2025 (from $(0.27) in Q3 2024) and $(1.26) for the nine months (from $(0.40) in 9M 2024).
• A derivative liability of $624,041 was recognized, contributing to total other expenses.

Risks

• Forward-looking statements involve known and unknown risks, uncertainties, and other factors that may cause actual results to differ materially from anticipated results.
• Additional risks and uncertainties are detailed in the Company's Registration Statement Under the Securities Act of 1933 on Form S-1, including the discussion under 'Risk Factors' therein.

Future Outlook

Management is focused on driving sustainable growth across pharmaceutical logistics, emergency preparedness, and specialty distribution operations, while actively pursuing strategic opportunities in complementary high-growth markets that leverage the company's established skill set.

Management Comments

• "Callan JMB continues to execute with excellence across our core business lines, while also leveraging our key competencies to expand into target growth areas."
• "We recently launched into the food sampling sector, as a natural extension of our core capabilities and part of our multi-variant strategic growth initiatives."
• "We have also made progress to support the onshoring of logistics operations to the U.S. in the future, particularly for international companies operating in the pharmaceutical space."
• "Our emergency preparedness business continues to perform well, with the City of Chicago extending our contract through June 2026 with an additional $1.5 million in funding, bringing the total contract value to $9.1 million and reinforcing our eight-year partnership."
• "These advancements reflect our commitment to delivering innovative solutions that meet evolving customer needs."
• "As we close out 2025, we are focused on driving sustainable growth across our pharmaceutical logistics, emergency preparedness, and specialty distribution operations while pursuing strategic opportunities in complementary high-growth markets that build on our established skill set."

Industry Context

Callan JMB operates in the integrative logistics sector, primarily serving the healthcare industry and emergency management agencies. Its focus on fulfillment, storage, monitoring, and cold chain logistics aligns with the growing demand for secure and compliant handling of medical materials and temperature-sensitive pharmaceuticals. The expansion into food sampling represents a diversification into an adjacent compliance-driven logistics market, while the India subsidiary and oral drug delivery equipment agreement reflect a strategic move towards international expansion and supporting pharmaceutical manufacturing onshoring.

Comparison to Industry Standards

• The filing does not provide specific comparable companies, projects, or results to assess Callan JMB's performance against global industry benchmarks. Therefore, a direct comparison is not feasible based solely on the provided information.

Related Party Transactions

• Related party loans were $0 as of September 30, 2025, down from $18,669 as of December 31, 2024, indicating a reduction or settlement of these loans.

Stakeholder Impact

• Shareholders: Experience significant dilution and increased losses per share, but may benefit from long-term strategic growth initiatives and market expansions.
• Customers: Benefit from extended contracts (e.g., City of Chicago) and enhanced technology (Sentry Monitoring System 4.0), indicating improved service reliability and capabilities.
• Employees: Implied stability and potential growth opportunities through business expansion into new sectors and international markets.
• Creditors: The increase in total liabilities, including a new derivative liability, could be a point of attention, though cash position has improved from financing activities.

Next Steps

• Drive sustainable growth across pharmaceutical logistics, emergency preparedness, and specialty distribution operations.
• Pursue strategic opportunities in complementary high-growth markets that build on established skill sets.
• Negotiate further operational agreements related to the oral drug delivery system manufacturing equipment installation.
• Advance plans for the temperature-controlled pharmaceutical storage and distribution warehouse in India and work with additional Indian companies for U.S. market entry.

Key Dates

Recommendation

While Callan JMB's Q3 2025 results show a significant increase in net losses and a slight revenue decline, the company is actively pursuing strategic growth initiatives, including expansion into food sampling, international markets (India), and securing key contract extensions (City of Chicago). The substantial increase in SG&A is partly attributable to public company costs, which may normalize. For a seasoned investor, the current financial performance is concerning, but the strategic moves could position the company for future growth. A 'hold' recommendation is appropriate to observe if these strategic initiatives can translate into improved financial performance and reduced losses in upcoming quarters, balancing the current poor profitability with potential long-term upside.

Keywords

logistics, healthcare logistics, cold chain, emergency preparedness, pharmaceutical storage, temperature monitoring, food sampling, supply chain, cGMP facility, Q3 2025 earnings